Acid-PEG4-Val-Cit-PAB-MMAE serves as a key linker-payload compound for making antibody-drug conjugates (ADCs). It includes:
- Acid Group: Conjugates easily to antibodies or targeting molecules.
- PEG4 Spacer: Adds solubility and flexibility, reducing steric hindrance during bioconjugation.
- Val-Cit Dipeptide: Acts as a protease-sensitive linker that cathepsin B cleaves, ensuring targeted drug release inside cells.
- PAB (p-Aminobenzyl) Linker: Works as a self-immolative spacer to help release the cytotoxic agent.
- MMAE (Monomethyl Auristatin E): Delivers potent antimitotic activity to halt cell division and trigger cell death.
Applications:
- Antibody-Drug Conjugates (ADCs): Enables targeted cancer therapy.
- Bioconjugation Research: Provides a model for studying linker stability and drug release mechanisms.
- Pharmaceutical Development: Helps design selective and effective anticancer drugs.
This compound directs MMAE specifically to cancer cells, reducing systemic side effects and boosting treatment effectiveness. After internalization, proteases cleave the Val-Cit linker, releasing MMAE to exert its cytotoxic effects.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
